



# Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study

Lena Mathews<sup>1,2</sup> · Dingfen Han<sup>1</sup> · Michele K. Evans<sup>3</sup> · Alan B. Zonderman<sup>3</sup> · Chiadi E. Ndumele<sup>1,2,4</sup> · Deidra C. Crews<sup>1,4</sup>

Received: 26 June 2020 / Revised: 27 January 2021 / Accepted: 28 January 2021 / Published online: 16 February 2021  
© W. Montague Cobb-NMA Health Institute 2021

## Abstract

**Objective** Guideline-directed medical therapy (GDMT) has been shown to improve outcomes for people with cardiovascular disease (CVD). Our goal was to assess racial and socioeconomic differences in GDMT use among a diverse population.

**Methods** We examined the cross-sectional association of race and poverty status with GDMT among 441 participants with CVD in a longitudinal cohort of urban-dwelling Black and White adults in Baltimore City, Maryland, using multivariable logistic regression. CVD status and GDMT were self-reported.

**Results** The participants' mean age was 60.5 (SD 8.5) years, with 61.7% women, 64.4% Black, and 46.9% living below poverty. Of the 126 participants with coronary artery disease (CAD), 37.3%, 54.8%, and 62.7% were on aspirin, antiplatelets, and statins, respectively. Black participants with CAD were less likely to be on aspirin, OR 0.29 (95% CI 0.13–0.67), and on combination GDMT (antiplatelet and statin), OR 0.36 (0.16–0.78) compared to Whites. There were no differences by poverty status in GDMT for CAD. Fully, 222 participants reported atrial fibrillation (AF), but only 10.5% were on anticoagulation with no significant difference by race or poverty status. The use of GDMT for heart failure and stroke was also low overall, but there were no differences by race or poverty status.

**Conclusions** Among an urban-dwelling population of adults, the use of secondary prevention of CVD was low, with lower aspirin and combination GDMT for Black participants with CAD. Efforts to improve GDMT use at the patient and provider levels may be needed to improve morbidity and mortality and reduce disparities in CVD.

**Keywords** Cardiovascular disease · Guideline-directed medical therapy · Socioeconomic status

Cardiovascular disease (CVD) is the leading cause of death worldwide [1]. For people with established CVD, guideline-directed medical therapies (GDMT) have been shown to

improve clinical outcomes. Aspirin and statins in individuals with coronary artery disease (CAD) and ischemic stroke [2, 3] anticoagulation in those with atrial fibrillation (AF) [4], and neurohormonal therapies ( $\beta$  blockers [BB], angiotensin converting enzyme inhibitors [ACE], aldosterone receptor blockers [ARB], mineralocorticoid receptor antagonists [MRA], and angiotensin receptor-neprilysin inhibitors [ARNI]) in people with heart failure with reduced ejection fraction (HF) have been shown to reduce recurrent events and mortality [5].

Racial disparities in cardiovascular outcomes have been documented, with a two-fold higher mortality rate in Black compared to White individuals [1]. These disparities may be in part due to socioeconomic factors [6]. Previous research showed that many eligible patients do not receive GDMT at hospital discharge or in the outpatient setting [7–12]. Most

✉ Lena Mathews  
lmathew6@jhmi.edu

<sup>1</sup> Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

<sup>2</sup> Division of Cardiology, Johns Hopkins School of Medicine, 600 North Wolfe Street Blalock 524D, Baltimore, MD, USA

<sup>3</sup> Laboratory of Epidemiology and Population Sciences, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD, USA

<sup>4</sup> Johns Hopkins Center for Health Equity, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

patients who are not prescribed GDMT at hospital discharge do not fill a prescription in the outpatient setting [13]. Furthermore, clinicians do not always initiate GDMT in stable outpatients [14]. The prevalence of the use of GDMT in CVD and whether it differs by race and/or socioeconomic status (SES) have not been explored in a contemporary diverse cohort. Understanding the distribution of GDMT among racial minorities and medically underserved individuals could lead to the identification of groups in need of targeted interventions to mitigate CVD disparities.

Our goal was to assess the prevalence of GDMT among individuals with established CVD in a socioeconomically diverse, bi-racial population of adults living in Baltimore City, and to determine whether there were differences by race and/or poverty status [15].

## Methods

### Study Design

This was a cross-sectional study of the association of race and poverty status with utilization of GDMT for CVD.

### Setting

We drew participants from the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study, a longitudinal cohort designed to investigate the relationships of race and SES with health [15]. The cohort consisted of Black and White adults in Baltimore City. Three thousand seven hundred twenty-two individuals aged 30–64 years, from 13 pre-determined neighborhoods (groups of contiguous census tracts) reflecting an area probability sample of Baltimore City, were enrolled beginning in 2004. The study was designed to sample a range of circumstances in a 4-way factorial cross of age (seven, 5-year age groups between 30 and 64), sex, race, and SES indexed by poverty status (below or above 125% of the Federal Poverty Guidelines for 2004).

### Participants

For our study, we included individuals with prevalent atherosclerotic CVD (myocardial infarction, stroke), AF, and HF by self-reporting who attended the HANDLS Wave 4 visit (between September 2013 and September 2017). We excluded individuals with missing information on the exposure, outcome, and key covariates in our primary adjustment model.

## Variables

Our exposures were race (Black vs. White) and poverty status (above vs. below). Our outcome was the self-reported use of GDMT: aspirin or antiplatelets and statins for atherosclerotic CVD (yes vs. no for each); anticoagulation for AF (yes vs. no); BB, ACE or ARB, and MRA for heart failure (yes vs. no for each). Covariates included were obtained from medical history, physical examination, laboratory measures, and a detailed questionnaire collected via a medical research vehicle at the Wave 4 visit. Medical history was obtained from a household survey and included self-reported race, age, highest education level attained, self-reported hypertension, diabetes, and medical insurance status. Physical exams were performed for the measurement of systolic blood pressure (mmHg), height (meters), and weight (kg); body mass index ( $\text{kg}/\text{m}^2$ ) was calculated. The diagnosis of hypertension was based upon either self-report, use of antihypertensive therapy, or measured average systolic blood pressure of  $\geq 140$  mmHg or diastolic blood pressure of  $\geq 90$  mmHg. The diagnosis of diabetes was based upon either self-report, use of anti-diabetic medications, or a measured fasting blood glucose of  $\geq 126$  mg/dL. Fasting blood tests were measured for hemoglobin A1c (%), estimated glomerular filtration rate (eGFR [ $\text{ml}/\text{min}$  per  $1.73\text{m}^2$ ]), and glucose (mg/dL) using a spectrophotometer (Olympus 5400; Quest Diagnostics).

### Statistical Methods

Baseline characteristics were stratified by race and poverty status. We used Student's *t* tests and Pearson chi-squared tests to compare continuous and categorical variables, respectively.

GDMT for CAD and stroke was considered to include aspirin or an antiplatelet, and statins, and was modeled individually or as a composite GDMT score (0 = neither aspirin/antiplatelet nor statin, 1 = either aspirin/antiplatelet or statin, 2 = aspirin/antiplatelet and statin). GDMT for CHF was considered to include BB, ACE/ARB, and MRA and was modeled individually or as a composite score (0 = no GDMT therapies, 1 = any one of the GDMT therapies, 2 = any 2 of the GDMT therapies, 3 = all 3 of GDMT therapies). GDMT for AF was considered to include warfarin, apixaban, or rivaroxaban and was also modeled as any anticoagulation.

Age and BMI were modeled as continuous variables. Education was modeled as a categorical variable (< high school; high school or equivalent; college or greater). Chronic kidney disease was defined as eGFR  $< 60$  ml/min per  $1.73\text{m}^2$ . Self-reported medical insurance status was modeled as a binary variable.

We performed multivariable logistic regression analyses for the association of race and poverty status with each component of GDMT individually and as a composite score for each of the CVD subtypes. We then adjusted for potential

confounders including age, sex, race, and poverty status (model 1). Race and poverty status were included as covariates if they were not the primary exposure for the model. Additionally, we adjusted for insurance status, body mass index ( $\text{kg}/\text{m}^2$ ), diabetes, hypertension, and eGFR (model 2).

All participants signed written informed consent. The National Institute of Environmental Health Sciences, National Institutes of Health, approved the study protocol. The HANDLS study was conducted in accordance with ethical principles set forth in the Declaration of Helsinki and requirements by the US code of Federal Regulation applicable to clinical studies. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines to prepare the manuscript [16]. Data analysis was performed using Stata 15.1 (Stata Corp, College Station, Texas).

## Results

A total of 2171 participants completed the HANDLS Wave 4 evaluation, and after excluding 1730 participants without CVD, our final study population was 441 (Supplemental Figure 1). The participants' mean age was 60.5 years (SD 8.5), 61.7% were women, 64.4% were Black, and 46.9% had income below poverty.

A total of 126 (28.6%) participants had CAD. Black individuals with CAD were more likely to use alcohol, have higher SBP, and have higher HDL-C (Table 1). Only 37.3% of participants with CAD were on aspirin, 54.8% were on antiplatelets (aspirin or another antiplatelet therapy), and 62.7% were on statins. Black participants with CAD had lower odds of being on aspirin compared to White participants [odds ratio (OR) 0.29 (95% CI 0.13–0.67)] in the fully adjusted model (Table 2). Participants with CAD who had incomes below poverty had higher use of antiplatelets and lower use of statins, but this did not reach statistical significance. When we examined the composite GDMT score, the log odds of being on GDMT for CAD was lower in Black participants (OR 0.36 [95% CI 0.16–0.78]).

A total of 229 (51.9%) participants reported a history of AF. Black participants with AF were more likely to have higher SBP, higher eGFR, and higher HDL-C (Table 1). The prevalence of anticoagulation use was 10.5%. There were no significant differences in the use of warfarin, apixaban, or rivaroxaban by race or poverty status (Table 2). When we examined the composite GDMT for any anticoagulation, there was also no significant difference by race or poverty status.

A total of 102 (23.1%) participants had a history of HF. White participants with HF were more likely to have < high school education, and lower HDL-C, as compared to Black participants (Table 1). Fully, 69.6% of participants with HF were on a BB, and 57.8% were on ACEIs or ARBs. However,

only 10.8% were on an MRA. There were no significant differences in the odds of individual or composite GDMT for HF by race or poverty status (Table 2).

A total of 102 (23.1%) participants reported a history of stroke. There were no significant differences in participant characteristics by race (Table 1). The use of statins, aspirin, and antiplatelets was all low in this population, at 44.1%, 15.7%, and 25.5%, respectively. There were no significant differences in the odds of individual therapies or composite GDMT for secondary prevention of stroke by race, and or poverty status (Table 2).

## Discussion

In a sample of adults living in Baltimore City, the self-reported use of evidence-based secondary prevention GDMT was low, with only about one-third of the participants with CAD being on aspirin, one-tenth of those with atrial fibrillation being on anticoagulation, and less than half of participants with a history of stroke being on antiplatelet therapy and statins. Among individuals with heart failure, the majority reported taking BB and ACE/ARB; however, the use of MRA was low. Black participants with CAD were less likely to be on aspirin and combination GDMT compared to White participants. These differences were not explained by guidelines, as they recommend uniform use of GDMT regardless of patient race. Contrary to our expectations, there were no differences in the use of GDMT for CVD by poverty status.

The prevalence of aspirin and statin use among survivors of myocardial infarction in the US is 28% and 72%, respectively, based upon the National Health and Nutrition Examination Survey data [17], while nationwide, only 47% of individuals with prior stroke are on statins [18]. These estimates are similar to our findings. Furthermore, our study was unique because, despite adjusting for demographic and clinical characteristics, we found that Black individuals with CAD had 71% lower odds of taking aspirin. The suboptimal use of aspirin and statins in this urban cohort is concerning because unlike many rural areas, urban-dwelling individuals often have more access to medical care by proximity. The benefits of aspirin and statins in reducing recurrent events in people with prior myocardial infarction have been well established when no contraindications are present [19]. Aspirin is a cornerstone for secondary prevention therapies and is associated with a 22% reduction in subsequent vascular events [20]. Similarly statins have been shown to reduce the risk of recurrent events by 25% [21]. That only 37% of individuals with CAD and that there were racial differences in aspirin use, is a troubling finding and underscores the gap in implementation of evidence-based therapies.

The benefits of anticoagulation among individuals with atrial fibrillation to prevent stroke in the absence of

**Table 1** Baseline characteristics by race and CVD subtype, the HANDLS study

Characteristic	Overall		CAD		Atrial fibrillation		CHF		Stroke		p value
	No.	p value	Whites	Blacks	Whites	Blacks	Whites	Blacks	Whites	Blacks	
No.	441		55	71	92	137	30	72	26	76	
Age, mean (SD)	60.5 (8.5)	0.50	61.3 (8.0)	62.3 (7.9)	61.1 (8.6)	59.6 (9.2)	63.8 (6.6)	61.1 (8.1)	62.2 (8.6)	60.1 (8.1)	0.27
Female	272 (61.7%)	1.00	28 (51%)	37 (52%)	61 (66.3%)	84 (61.3%)	20 (67%)	55 (76%)	15 (58%)	49 (64%)	0.64
Poverty status	207 (46.9%)	0.86	24 (44%)	33 (46%)	33 (35.9%)	65 (47.4%)	14 (47%)	43 (60%)	15 (58%)	40 (53%)	0.82
<i>Education</i>											
<High School	158 (35.8%)	0.19	23 (42%)	19 (27%)	31 (33.7%)	44 (32.1%)	15 (50%)	23 (32%)	10 (38%)	33 (43%)	0.88
High school or Equivalent	143 (32.4%)		15 (27%)	27 (38%)	25 (27.2%)	46 (33.6%)	6 (20%)	34 (47%)	9 (35%)	26 (34%)	
College or higher	140 (31.7%)		17 (31%)	25 (35%)	36 (39.1%)	47 (34.3%)	9 (30%)	15 (21%)	7 (27%)	17 (22%)	
<i>Cigarette status</i>											
Never tried	45 (11.4%)	0.29	5 (10%)	7 (11%)	12 (15.0%)	17 (14.0%)	3 (10%)	4 (7%)	3 (13%)	3 (4%)	0.40
Tried, never used regularly	31 (7.8%)		2 (4%)	4 (6%)	6 (7.5%)	13 (10.7%)	2 (7%)	3 (5%)	0 (0%)	3 (4%)	
Former user	136 (34.4%)		15 (31%)	29 (45%)	35 (43.8%)	33 (27.3%)	11 (38%)	21 (36%)	8 (33%)	30 (42%)	
Current user	183 (46.3%)		27 (55%)	24 (38%)	27 (33.8%)	58 (47.9%)	13 (45%)	30 (52%)	13 (54%)	36 (50%)	
<i>Alcohol use</i>											
Never tried	18 (4.6%)	0.02	3 (7%)	5 (8%)	3 (3.8%)	5 (4.1%)	0 (0%)	4 (7%)	1 (5%)	3 (4%)	0.27
Tried, never used regularly	26 (6.6%)		6 (13%)	2 (3%)	10 (12.7%)	5 (4.1%)	3 (12%)	5 (8%)	2 (9%)	2 (3%)	
Used > 6 months ago	170 (43.5%)		25 (54%)	23 (37%)	32 (40.5%)	51 (42.1%)	17 (65%)	26 (43%)	12 (55%)	29 (43%)	
Used in past 6 months	177 (45.3%)		12 (26%)	32 (52%)	34 (43.0%)	60 (49.6%)	6 (23%)	25 (42%)	7 (32%)	34 (50%)	
Health insurance	80 (18.9%)	0.64	9 (16%)	14 (21%)	10 (11.2%)	28 (21.2%)	3 (10%)	12 (17%)	2 (8%)	13 (18%)	0.34
BMI kg/m <sup>2</sup> , mean (SD)	31.9 (8.9)	0.82	31.5 (7.4)	31.1 (8.4)	33.1 (8.9)	30.9 (8.4)	35.3 (10.6)	34.1 (11.0)	29.2 (7.5)	31.5 (9.3)	0.28
SBP, mean (SD)	119.1 (27.4)	0.046	112.2 (31.8)	123.3 (29.9)	113.5 (25.3)	123.1 (22.8)	117.0 (30.2)	121.2 (36.8)	120.5 (20.1)	127.5 (26.6)	0.22
eGFR, mean (SD)	79.5 (25.7)	0.37	73.6 (18.8)	77.6 (27.8)	76.9 (21.2)	84.9 (25.6)	64.1 (23.1)	64.7 (34.6)	77.2 (21.4)	81.5 (24.3)	0.44
HDL mg/dL, mean (SD)	55.2 (19.6)	0.008	46.3 (12.1)	53.8 (17.0)	49.6 (16.1)	60.4 (23.1)	45.5 (12.2)	58.5 (20.8)	47.8 (13.2)	56.2 (19.8)	0.052
HbA1c %, mean (SD)	6.5 (1.6)	0.21	7.1 (2.1)	6.7 (1.5)	6.3 (1.4)	6.5 (1.5)	7.1 (1.6)	6.5 (1.5)	6.7 (1.6)	6.4 (1.6)	0.49
Hypertension	360 (81.6%)	0.39	47 (85%)	65 (92%)	70 (76.1%)	110 (80.3%)	28 (93%)	69 (96%)	17 (65%)	62 (82%)	0.11
Diabetes	164 (37.2%)	0.47	23 (42%)	35 (49%)	29 (31.5%)	48 (35.0%)	18 (60%)	35 (49%)	10 (38%)	28 (37%)	1.00
CKD	73 (16.6%)	0.26	8 (15%)	17 (24%)	13 (14.1%)	18 (13.1%)	5 (17%)	25 (35%)	3 (12%)	11 (14%)	1.00
CAD	126 (28.6%)	0.11	3 (5%)	71 (100%)	13 (14.1%)	18 (13.1%)	8 (27%)	18 (25%)	3 (12%)	10 (13%)	1.00
Stroke	102 (23.1%)	0.82	13 (24%)	10 (14%)	9 (9.8%)	20 (14.6%)	5 (17%)	10 (14%)	26 (100%)	76 (100%)	0.46
AF	229 (51.9%)	0.14	3 (5%)	18 (25%)	92 (100.0%)	137 (100.0%)	15 (50%)	16 (22%)	9 (35%)	20 (26%)	0.52
CHF	102 (23.1%)	0.005	8 (15%)	18 (25%)	15 (16.3%)	16 (11.7%)	30 (100%)	72 (100%)	5 (19%)	10 (13%)	0.55
Aspirin	104 (23.6%)	0.79	28 (51%)	19 (27%)	27 (29.3%)	20 (14.6%)	16 (53%)	16 (22%)	5 (19%)	11 (14%)	0.57
MRA	18 (4.1%)	0.14	2 (4%)	3 (3%)	3 (3.3%)	8 (5.8%)	3 (10%)	8 (11%)	0 (0%)	3 (4%)	0.55
ARB	66 (15.0%)	0.35	5 (9%)	13 (18%)	18 (19.6%)	25 (18.2%)	8 (27%)	9 (13%)	5 (19%)	11 (14%)	0.46
ACEI	138 (31.3%)	0.67	18 (33%)	29 (41%)	21 (22.8%)	41 (29.9%)	12 (40%)	30 (42%)	10 (38%)	22 (29%)	0.81
Beta blocker	190 (43.1%)	0.58	32 (58%)	44 (62%)	33 (35.9%)	56 (40.9%)	18 (60%)	53 (74%)	7 (27%)	24 (32%)	0.64
Anticoagulation	33 (7.5%)	0.19	8 (15%)	8 (11%)	12 (13.0%)	12 (8.8%)	3 (10%)	6 (8%)	2 (8%)	4 (5%)	0.12
Statin	196 (44.4%)	0.30	38 (69%)	41 (58%)	43 (46.7%)	42 (30.7%)	19 (63%)	33 (46%)	15 (58%)	30 (39%)	0.024
Any antiplatelets	135 (30.6%)	0.30	33 (60%)	36 (51%)	28 (30.4%)	30 (21.9%)	17 (57%)	22 (31%)	7 (27%)	19 (25%)	1.00

Legend: Baseline characteristics stratified by race. Abbreviations: SD standard deviation, HDL high-density lipoprotein, ACE inhibitor angiotensin converting enzyme inhibitor, GFR glomerular filtration rate, CKD defined as estimated GFR < 60 ml/min/1.73<sup>2</sup>

**Table 2** Guideline directed medical therapy for specific cardiovascular diseases, by race and poverty status.

Coronary artery disease	Aspirin		Anti-Platelets		Statin		GDMT	
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
Black v. White	0.34** [0.16,0.72]	0.29*** [0.13,0.67]	0.63 [0.30,1.31]	0.58 [0.26,1.33]	0.60 [0.28,1.28]	0.47 [0.20,1.13]	0.44* [0.22,0.90]	0.36* [0.16,0.78]
Below v. Above Poverty	1.08 [0.50,2.32]	1.30 [0.57,2.94]	1.52 [0.72,3.19]	1.99 [0.88,4.50]	0.54 [0.25,1.15]	0.51 [0.22,1.17]	0.83 [0.41,1.66]	0.95 [0.45,1.99]
No.	126	116	126	116	126	116	126	116
Congestive heart failure	ACE or ARB		MRA		Beta Blocker		GDMT	
Black v. White	0.73 [0.30,1.80]	0.68 [0.24,1.92]	0.93 [0.22,3.99]	0.98 [0.19,5.07]	1.75 [0.69,4.42]	1.39 [0.48,4.09]	1.28 [0.43,3.84]	0.84 [0.22,3.16]
Below v. Above Poverty	0.62 [0.27,1.43]	0.62 [0.24,1.58]	4.11 [0.79,21.38]	4.52 [0.72,28.56]	1.83 [0.75,4.50]	1.86 [0.68,5.13]	2.25 [0.78,6.54]	1.45 [0.43,4.95]
No.	102	88	102	88	102	88	102	89
Atrial Fibrillation	Warfarin		Apixaban		Rivaroxaban		GDMT	
Black v. White	1.14 [0.39,3.29]	0.63 [0.19,2.08]	0.33 [0.03,3.76]	0.05 [0.001,2.54]	0.17 [0.02,1.61]	0.16 [0.02,1.57]	0.65 [0.28,1.53]	0.39 [0.15,1.04]
Below Poverty v. Above Poverty	1.48 [0.52,4.18]	2.25 [0.73,6.93]	2.84 [0.25,33.01]	19.07 [0.41,894.6]	0.39 [0.04,3.66]	0.41 [0.04,4.09]	1.27 [0.53,3.03]	1.84 [0.72,4.73]
No.	229	182	145	115	229	159	229	182
Stroke	Aspirin		Anti-Platelets		Statin		GDMT	
Black v. White	0.72 [0.22,2.36]	1.41 [0.25,7.86]	0.96 [0.34,2.75]	1.34 [0.33,5.41]	0.50 [0.20,1.27]	0.43 [0.14,1.34]	0.69 [0.29,1.68]	0.77 [0.27,2.20]
Below Poverty v. Above Poverty	0.61 [0.20,1.82]	0.37 [0.09,1.53]	1.01 [0.40,2.54]	0.75 [0.23,2.41]	0.82 [0.37,1.85]	0.96 [0.38,2.42]	0.95 [0.44,2.06]	0.91 [0.37,2.24]
No.	102	86	102	86	102	86	102	86

Model 1 is adjusted for age, sex, poverty status

Model 2 is additionally adjusted for insurance status, body mass index, diabetes, hypertension, estimated glomerular filtration rate

Exponentiated coefficients; 95% confidence intervals in brackets

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$

GDMT for CAD and Stroke includes aspirin or antiplatelets and statin

GDMT for HF includes BB, MRA, ACE or ARB

GDMT for AF includes any combination of warfarin, apixaban or rivaroxaban

contraindications have been clearly demonstrated, with a 33% lower stroke risk with anticoagulation [22]. Anticoagulation is recommended in the majority of older adults with AF who have at least one CVD comorbidity based on a clinical risk score [23]. In a large US registry of patients with AF, over 80% were on anticoagulation [24], and in a study of Medicare beneficiaries with an indication for anticoagulation, 53% were prescribed anticoagulation [25]. However, in our study of adults in a “real-world” setting, the prevalence of individuals on anticoagulation was much lower at 10.5%. A recently published large registry study also showed racial differences in anticoagulation, and while our results were in the same direction, they were not statistically significant [24]. Anticoagulation is associated with bleeding risk, but in carefully selected patients, the benefits of anticoagulation in stroke prevention outweighs the risk of bleeding.

We found that the use of neurohormonal blocking medications for patients with HF were lower than those reported in national registries for ACE/ARB and BB but similar for MRA [26], with modest proportions reporting using ACE/ARB (57.8%) and BB (69.6%) and low use of MRA (10.8%). We were unable to further characterize the HF population by left ventricular function, which would be an important focus for future studies.

Our findings should be interpreted in the context of several limitations including (1) the cross-sectional design which limited our ability to attribute causation; (2) self-reported medications and disease status may have resulted in a bias by indication; (3) likely residual confounding of the association of race, SES, and GDMT; (4) lack of complete data on left ventricular ejection fraction to ascertain whether participants had heart failure with reduced vs. preserved ejection fraction; (5) lack of a measure of medication adherence; (6) potential survival bias given that individuals who survived to HANDLS wave 4 may have been those who were more adherent to GDMT; and (7) a small sample size which may have resulted in a lack of power to detect statistically significant associations. Nonetheless, our study had several strengths, including being a well-characterized, diverse cohort by age, race, and poverty status, and with measures captured in a contemporary time period likely to reflect recent prescribing patterns.

The mechanisms between race/poverty status and GDMT use are complex and our findings have implications at the provider and individual level. Education of providers about current clinical practice guidelines and incentivizing providers for adhering to guidelines may improve prescription of GDMT and promote consistency and equity in care by race and SES. At the individual level, factors such as patient-provider communication, health literacy, and knowledge of disease self-care may play a large role in lack of GDMT especially in individuals with low SES [27]. Efforts towards measuring and improving medication adherence through education, patient engagement, and cognitive-behavioral intervention are

desperately needed as lack of adherence hinders effective treatment of various CVD conditions. Furthermore, reducing barriers to access to specialty care (e.g., cardiology) may result in higher GDMT use among those with CVD.

In conclusion, among a sample of adults in Baltimore City, the self-reported use of evidence-based secondary prevention medications was low, with only 37% of participants with CAD being on aspirin, 11% with AF being on anticoagulation, and less than 50% of participants with a history of stroke being on antiplatelet therapy and statins. Among individuals with HF, nearly 70% were taking BB; however, the use of ACE/ARB and MRA were 58% and 11%, respectively. Black participants with CAD were less likely to be on aspirin and combination GDMT, but there were no other significant differences in the use of GDMT by race or poverty status. Our findings were robust to adjustment for multiple sociodemographic and clinical factors. Significant gaps exist in secondary prevention and efforts targeted at both the patient and provider levels could substantially improve morbidity and mortality from CVD.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s40615-021-00984-y>.

**Authors' Contributions** LM (design and concept of study, data analysis and interpretation, manuscript draft); DH (data analysis and interpretation, statistical expertise, manuscript draft, supervision); MKE (acquisition of data, manuscript draft, supervision); ABZ (acquisition of data, manuscript draft, supervision); CEN (manuscript draft), and DCC (design and concept of study, data analysis and interpretation, manuscript draft, supervision).

**Funding** This work was supported in part by the Intramural Research Program of the National Institutes of Health (NIH), National Institute on Aging (A.B.Z and M.K.E). This work was also supported by Diversity Supplement under ARIC Contract Grant Number Contract HHSN268201700002I/ 75N92019F00074 from the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) (L.M), the Johns Hopkins University President's Frontier Award (D.C.C), and grant K24 HL148181 from the National Heart, Lung and Blood Institute, NIH (D.C.C). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

**Data Availability** The study data will not be made available to other researchers for the purposes of reproducing the results or replicating the procedure because of human subjects' restrictions.

**Code Availability** The code is available for replication of the results.

## Declarations

**Conflict of Interest** The authors declare no conflicts of interest.

**Ethics Approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the National Institutes of Health and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the National Institute of Health.

**Consent to Participate** Informed consent was obtained from all participants included in the study.

**Consent for Publication** The authors affirm that human research participants provided informed consent for publication of all the materials. Authors are responsible for correctness of the statements provided in the manuscript. **Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s40615-021-00984-y>.


## References

- Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 update: a report from the American Heart Association. *Circulation*. 2017;135(10):e146–603. <https://doi.org/10.1161/CIR.0000000000000485>.
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S1–45. <https://doi.org/10.1161/01.cir.0000437738.63853.7a>.
- Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. *Circulation*. 2011;124(22):2458–73. <https://doi.org/10.1161/CIR.0b013e318235eb4d>.
- January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation*. 2014;130(23):2071–104. <https://doi.org/10.1161/CIR.0000000000000040>.
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. 2017;136(6):e137–e61. <https://doi.org/10.1161/CIR.0000000000000509>.
- Karlamangla AS, Merkin SS, Crimmins EM, Seeman TE. Socioeconomic and ethnic disparities in cardiovascular risk in the United States, 2001–2006. *Ann Epidemiol*. 2010;20(8):617–28. <https://doi.org/10.1016/j.annepidem.2010.05.003>.
- Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, et al. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. *J Am Coll Cardiol*. 2013;61(1):35–40. <https://doi.org/10.1016/j.jacc.2012.08.1019>.
- Lin I, Sung J, Sanchez RJ, Mallya UG, Friedman M, Panaccio M, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. *J Manag Care Spec Pharm*. 2016;22(6):685–98. <https://doi.org/10.18553/jmcp.2016.22.6.685>.
- Parameswaran AC, Tang WH, Francis GS, Gupta R, Young JB. Why do patients fail to receive beta-blockers for chronic heart failure over time? A “real-world” single-center, 2-year follow-up experience of beta-blocker therapy in patients with chronic heart failure. *Am Heart J*. 2005;149(5):921–6. <https://doi.org/10.1016/j.ahj.2004.07.026>.
- Patel P, White DL, Deswal A. Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. *Am Heart J*. 2007;153(4):515–22. <https://doi.org/10.1016/j.ahj.2007.01.037>.
- Shahar E, Folsom AR, Romm FJ, Bisgard KM, Metcalf PA, Crum L, et al. Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J*. 1996;131(5):915–22.
- Glasser SP, Cushman M, Prineas R, Kleindorfer D, Prince V, You Z, et al. Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? *Prev Med*. 2008;47(2):161–6. <https://doi.org/10.1016/j.ypmed.2008.05.009>.
- Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. *Am Heart J*. 2013;165(6):979–86 e1. <https://doi.org/10.1016/j.ahj.2013.03.007>.
- Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. *J Am Coll Cardiol*. 2019;73(19):2365–83. <https://doi.org/10.1016/j.jacc.2019.02.015>.
- Evans MK, Lepkowski JM, Powe NR, LaVeist T, Kuczmarski MF, Zonderman AB. Healthy aging in neighborhoods of diversity across the life span (HANDLS): overcoming barriers to implementing a longitudinal, epidemiologic, urban study of health, race, and socioeconomic status. *Ethn Dis*. 2010;20(3):267–75.
- Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology*. 2007;18(6):805–35. <https://doi.org/10.1097/EDE.0b013e3181577511>.
- Shah NS, Huffman MD, Ning H, Lloyd-Jones DM. Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999–2012. *J Am Heart Assoc*. 2015;4(4). <https://doi.org/10.1161/JAHA.114.001709>.
- Shah NS, Huffman MD, Ning H, Lloyd-Jones DM. Trends in vascular risk factor treatment and control in US stroke survivors: the National Health and Nutrition Examination Surveys (1999–2010). *Circ Cardiovasc Qual Outcomes*. 2013;6(3):270–7. <https://doi.org/10.1161/CIRCOUTCOMES.113.000112>.
- Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*. 2009;373(9678):1849–60. [https://doi.org/10.1016/S0140-6736\(09\)60503-1](https://doi.org/10.1016/S0140-6736(09)60503-1).
- Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324(7329):71–86. <https://doi.org/10.1136/bmj.324.7329.71>.
- Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, et al. Effectiveness of statin therapy in adults with coronary heart disease. *Arch Intern Med*. 2004;164(13):1427–36. <https://doi.org/10.1001/archinte.164.13.1427>.
- Amin A. Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. *Clin Interv Aging*. 2013;8:75–84. <https://doi.org/10.2147/CIA.S37818>.
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010;137(2):263–72. <https://doi.org/10.1378/chest.09-1584>.

24. Essien UR, Holmes DN, Jackson LR 2nd, Fonarow GC, Mahaffey KW, Reiffel JA, et al. Association of race/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. *JAMA Cardiol.* 2018;3:1174. <https://doi.org/10.1001/jamacardio.2018.3945>.
25. Baik SH, Hernandez I, Zhang Y. Evaluating the initiation of novel oral anticoagulants in Medicare beneficiaries. *J Manag Care Spec Pharm.* 2016;22(3):281–92. <https://doi.org/10.18553/jmcp.2016.22.3.281>.
26. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghide M, Heywood JT, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). *Circulation.* 2010;122(6):585–96. <https://doi.org/10.1161/CIRCULATIONAHA.109.934471>.
27. Ferdinand KC, Yadav K, Nasser SA, Clayton-Jeter HD, Lewin J, Cryer DR, et al. Disparities in hypertension and cardiovascular disease in blacks: the critical role of medication adherence. *J Clin Hypertens (Greenwich).* 2017;19(10):1015–24. <https://doi.org/10.1111/jch.13089>.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Supplemental Figure 1:** Derivation of the study population.

Supplemental Table 1: Baseline characteristics by poverty status, the HANDLS study

Characteristic	CAD				Atrial Fibrillation			CHF			Stroke		
	Overall	Above	Below	p-value	Above	Below	p-value	Above	Below	p-value	Above	Below	p-value
<b>No.</b>	<b>441</b>	<b>69</b>	<b>57</b>		<b>131</b>	<b>98</b>		<b>45</b>	<b>57</b>		<b>47</b>	<b>55</b>	
Age, mean (SD)	60.5 (8.5)	63.2 (7.3)	60.3 (8.3)	0.037	61.2 (8.8)	58.9 (9.1)	0.056	63.3 (6.8)	60.8 (8.4)	0.098	61.3 (8.5)	60.1 (8.1)	0.49
Female	272 (61.7%)	36 (52%)	29 (51%)	1.00	80 (61.1%)	65 (66.3%)	0.49	28 (62%)	47 (82%)	0.025	28 (60%)	36 (65%)	0.68
Black	284 (64.4%)	38 (55%)	33 (58%)	0.86	72 (55.0%)	65 (66.3%)	0.10	29 (64%)	43 (75%)	0.28	36 (77%)	40 (73%)	0.82
<b>Education</b>													
< High School	158 (35.8%)	20 (29%)	22 (39%)	0.28	35 (26.7%)	40 (40.8%)	0.031	14 (31%)	24 (42%)	0.12	18 (38%)	25 (45%)	0.63
High School or Equivalent	143 (32.4%)	22 (32%)	20 (35%)		40 (30.5%)	31 (31.6%)		16 (36%)	24 (42%)		16 (34%)	19 (35%)	
College or Greater	140 (31.7%)	27 (39%)	15 (26%)		56 (42.7%)	27 (27.6%)		15 (33%)	9 (16%)		13 (28%)	11 (20%)	
<b>Cigarette Status</b>													
Never tried	45 (11.4%)	6 (10%)	6 (11%)	0.18	19 (16.8%)	10 (11.4%)	0.002	3 (8%)	4 (8%)	1.00	3 (7%)	3 (6%)	0.037
Tried, never used regularly	31 (7.8%)	5 (8%)	1 (2%)		16 (14.2%)	3 (3.4%)		2 (5%)	3 (6%)		3 (7%)	0 (0%)	
Former user	136 (34.4%)	26 (44%)	18 (33%)		42 (37.2%)	26 (29.5%)		14 (36%)	18 (38%)		22 (49%)	16 (31%)	
Current user	183 (46.3%)	22 (37%)	29 (54%)		36 (31.9%)	49 (55.7%)		20 (51%)	23 (48%)		17 (38%)	32 (63%)	
<b>Alcohol use</b>													
Never tried	18 (4.6%)	3 (5%)	5 (11%)	0.29	2 (1.7%)	6 (7.2%)	0.24	2 (5%)	2 (4%)	0.76	0 (0%)	4 (8%)	0.34
Tried, never used regularly	26 (6.6%)	5 (8%)	3 (6%)		8 (6.8%)	7 (8.4%)		4 (10%)	4 (9%)		2 (5%)	2 (4%)	
Used >6 months ago	170 (43.5%)	24 (39%)	24 (51%)		49 (41.9%)	34 (41.0%)		17 (44%)	26 (55%)		20 (49%)	21 (43%)	
Used in past 6 months	177 (45.3%)	29 (48%)	15 (32%)		58 (49.6%)	36 (43.4%)		16 (41%)	15 (32%)		19 (46%)	22 (45%)	
Health Insurance	80 (18.9%)	11 (16%)	12 (22%)	0.49	16 (12.6%)	22 (23.4%)	0.047	4 (9%)	11 (20%)	0.16	7 (16%)	8 (15%)	1.00
BMI kg/m <sup>2</sup> , mean (SD)	31.9 (8.9)	31.6 (8.2)	30.8 (7.7)	0.58	32.2 (8.9)	31.3 (8.4)	0.44	34.4 (11.5)	34.5 (10.4)	0.94	32.6 (9.2)	29.5 (8.5)	0.083
SBP, mmHg, mean (SD)	119.1 (27.4)	112.5 (36.1)	125.9 (21.6)	0.015	118.1 (24.6)	120.9 (23.7)	0.38	119.8 (32.5)	120.0 (36.9)	0.98	126.0 (22.1)	125.4 (27.7)	0.90
eGFR, mean (SD)	79.5 (25.7)	73.3 (23.4)	79.0 (25.3)	0.20	83.0 (23.2)	80.0 (25.6)	0.36	63.6 (32.8)	65.2 (30.9)	0.80	85.8 (20.7)	75.8 (25.0)	0.042
HDL mg/dL, mean (SD)	55.2 (19.6)	51.9 (14.0)	49.1 (17.2)	0.33	57.0 (22.6)	54.9 (19.3)	0.47	54.7 (21.5)	54.6 (18.1)	0.98	52.2 (15.4)	55.4 (20.9)	0.40
HbA1c %, mean (SD)	6.5 (1.6)	6.7 (1.6)	7.0 (2.0)	0.28	6.4 (1.5)	6.4 (1.4)	0.93	6.7 (1.6)	6.6 (1.5)	0.70	6.7 (1.6)	6.3 (1.6)	0.25
Hypertension	360 (81.6%)	60 (87%)	52 (91%)	0.57	102 (77.9%)	78 (79.6%)	0.87	41 (91%)	56 (98%)	0.17	34 (72%)	45 (82%)	0.34
Diabetes	164 (37.2%)	32 (46%)	26 (46%)	1.00	48 (36.6%)	29 (29.6%)	0.32	25 (56%)	28 (49%)	0.55	20 (43%)	18 (33%)	0.41
CKD	73 (16.6%)	12 (17%)	13 (23%)	0.50	17 (13.0%)	14 (14.3%)	0.85	9 (20%)	21 (37%)	0.081	5 (11%)	9 (16%)	0.57
CAD	126 (28.6%)	69 (100%)	57 (100%)		18 (13.7%)	13 (13.3%)	1.00	13 (29%)	13 (23%)	0.50	7 (15%)	6 (11%)	0.57
Stroke	102 (23.1%)	7 (10%)	6 (11%)	0.58	9 (6.9%)	20 (20.4%)	0.004	7 (16%)	8 (14%)	1.00	47 (100%)	55 (100%)	
AF	229 (51.9%)	18 (26%)	13 (23%)	0.015	131 (100.0%)	98 (100.0%)		17 (38%)	14 (25%)	0.19	9 (19%)	20 (36%)	0.078
CHF	102 (23.1%)	13 (19%)	13 (23%)	0.20	17 (13.0%)	14 (14.3%)	0.85	45 (100%)	57 (100%)		7 (15%)	8 (15%)	1.00
Aspirin	104 (23.6%)	26 (38%)	21 (37%)	0.33	31 (23.7%)	16 (16.3%)	0.19	17 (38%)	15 (26%)	0.28	9 (19%)	7 (13%)	0.42
MRA	18 (4.1%)	0 (0%)	4 (7%)	0.28	4 (3.1%)	7 (7.1%)	0.21	2 (4%)	9 (16%)	0.11	0 (0%)	3 (5%)	0.25
ARB	66 (15.0%)	11 (16%)	7 (12%)	0.57	25 (19.1%)	18 (18.4%)	1.00	8 (18%)	9 (16%)	0.80	6 (13%)	10 (18%)	0.59
ACEI	138 (31.3%)	22 (32%)	25 (44%)	1.00	32 (24.4%)	30 (30.6%)	0.37	21 (47%)	21 (37%)	0.42	16 (34%)	16 (29%)	0.67
Beta blocker	190 (43.1%)	45 (65%)	31 (54%)	0.50	48 (36.6%)	41 (41.8%)	0.49	28 (62%)	43 (75%)	0.19	13 (28%)	18 (33%)	0.67
Anticoagulation	33 (7.5%)	10 (14%)	6 (11%)	0.58	13 (9.9%)	11 (11.2%)	0.83	4 (9%)	5 (9%)	1.00	3 (6%)	3 (5%)	1.00
Statin	196 (44.4%)	48 (70%)	31 (54%)	0.015	48 (36.6%)	37 (37.8%)	0.89	25 (56%)	27 (47%)	0.43	22 (47%)	23 (42%)	0.69
Any antiplatelets	135 (30.6%)	36 (52%)	33 (58%)	0.20	37 (28.2%)	21 (21.4%)	0.28	20 (44%)	19 (33%)	0.31	12 (26%)	14 (25%)	1.00